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ARTICLE OPEN
Oxytocin modulates hippocampal perfusion in people at
clinical high risk for psychosis
Cathy Davies1, Yannis Paloyelis 2, Grazia Rutigliano1, Marco Cappucciati1, Andrea De Micheli1,3, Valentina Ramella-Cravaro 1,
Umberto Provenzani1,4, Mathilde Antoniades3,5, Gemma Modinos 2,5, Dominic Oliver1, Daniel Stahl 6, Silvia Murguia7,
Fernando Zelaya2, Paul Allen5,8, Sukhi Shergill5, Paul Morrison5, Steve Williams2, David Taylor9, Philip McGuire3,5,10 and
Paolo Fusar-Poli1,3,4,10
Preclinical and human studies suggest that hippocampal dysfunction is a key factor in the onsetQ1 of psychosis. People at Clinical
High Risk for psychosis (CHR-P) present with a clinical syndrome that can include social withdrawal and have a 20–35% risk of
developing psychosis in the next 2 years. Recent research shows that resting hippocampal blood flow is altered in CHR-P individuals
and predicts adverse clinical outcomes, such as non-remission/transition to frank psychosis. Previous work in healthy males
indicates that a single dose of intranasal oxytocin has positive effects on social function and marked effects on resting hippocampal
blood flow. The present study examined the effects of intranasal oxytocin on hippocampal blood flow in CHR-P individuals. In a
double-blind, placebo-controlled, crossover design, 30 CHR-P males were studied using pseudo-continuous Arterial Spin Labelling
on 2 occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on left hippocampal blood flow
were examined in a region-of-interest analysis of data acquired at 22–28 and at 30–36minutes post-intranasal administration.
Relative to placebo, administration of oxytocin was associated with increased hippocampal blood flow at both time points (p
= .0056; p= .034), although the effect at the second did not survive adjustment for the effect of global blood flow. These data
indicate that oxytocin can modulate hippocampal function in CHR-P individuals and therefore merits further investigation as a
candidate novel treatment for this group.
Neuropsychopharmacology (2019) 0:1–10; https://doi.org/10.1038/s41386-018-0311-6
INTRODUCTION
At present, there is a lack of effective treatments for individuals at
Clinical High Risk of Psychosis (CHR-P [1]). Recent studies suggest
that existing interventions do not significantly impact on
transition to psychosis [2], attenuated positive [3] or negative
symptoms [4], or social and functional outcomes [5]. Novel
treatments for this population are therefore needed [6].
A substantial body of scientific work places aberrant hippo-
campal structure and function at the core of neurobiological
mechanisms underlying the onset of psychosis [7]. Evidence from
post-mortem, neuroimaging and preclinical research suggests that
the onset of attenuated psychotic symptoms may be driven by
dysregulated glutamate neurotransmission in the Cornu Ammonis
1 (CA1) region of the hippocampus, which is thought to lead to
hypermetabolism and altered (increased) blood flow [7–10].
Enhanced glutamatergic tone in CA1 induces allostatic adapta-
tions [11] in γ-aminobutyric acid (GABA)-ergic neurotransmission,
with consequent disinhibition of pyramidal neurons (Fig. 1) [12].
These changes may lead to disturbed neural excitation/inhibition
balance, and via polysynaptic projection pathways to the
midbrain/striatum, to midbrain hyperdopaminergia [13, 14]. As
the CHR-P state progresses to the first episode of psychosis, the
functional perturbations once localised to (particularly the left)
CA1 may spread to extra-hippocampal regions such as the frontal
cortex [7, 8], and excitotoxic as well as atrophic processes
culminate in hippocampal volume loss -structural changes-
beginning in CA1 [15–17]. These findings are consistent with
evidence that CHR-P individuals show increased resting regional
cerebral blood flow (rCBF) in the hippocampus relative to controls
[18, 19], and normalisation (reduction) of left hippocampal rCBF is
associated with remission from the CHR-P state [18]. Hippocampal
rCBF in CHR-P individuals has also been correlated with cortical
GABA levels [20]. Q2
The neuropeptide oxytocin is a key modulator of social, sexual
and emotional processes [21], including hypothalamic-pituitary-
adrenal axis regulation [22], emotion recognition [23], social
memory [24] and reward, and possesses anxiolytic [21, 22] and
prosocial properties [25, 26]. Previous work in healthy males [27]
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suggests that an acute dose of intranasal oxytocin significantly
increases rCBF in limbic and midbrain regions, including the
hippocampus. Preclinical studies have also identified the hippo-
campus as a key target for oxytocin-mediated effects, with
oxytocin enhancing the signal-to-noise ratio of CA1 pyramidal cell
firing by selectively targeting GABAergic interneuron function [28,
29]—part of the neural circuit implicated in psychosis onset [6, 12,
14]. Oxytocin is further linked to these mechanisms via its role in
neural circuit maturation in the pre and peri-natal period,
responsible for the excitatory-to-inhibitory switching of GABAergic
signalling [30], and controlling dendrite complexity [31], synapse
density [31] and the onset of synchronous firing in developing
hippocampal pyramidal neurons [32]. Preclinical research also
indicates that oxytocin can protect hippocampal CA1 plasticity
and memory from the effects of stress [33], which is also
implicated in the onset of psychosis [13].Q3
The aim of the present study was to examine the acute effects
of oxytocin on hippocampal rCBF in CHR-P individuals. We focused
on the left (and not right) hippocampus because previous CHR-P
research has repeatedly implicated the left hippocampus in the
pathophysiology of psychosis risk [7, 8, 10, 18, 20, 34, 35], with left
(and not right) hippocampal rCBF associated with clinical
outcomes [18]. In addition, previous oxytocin research has
reported distinctly left-lateralised effects of oxytocin on cerebral
blood flow [27]. In view of evidence that certain subregions of the
hippocampus may be particularly involved in the risk for
psychosis, and may be particularly influenced by oxytocin, we
also investigated whether the effects of oxytocin were specific to
different hippocampal subregions. Finally, we explored whether
oxytocin had additional effects outside the hippocampal region in
a whole-brain analysis. The a priori evidence for altered
hippocampal rCBF in CHR-P individuals vs controls comes from
the same clinical sample as the current study—recruited from the
Outreach And Support in South London (OASIS) service [36]—and
has already been replicated in a further sample recruited from this
clinic [18, 19]. Leveraging these findings, the current study
adopted a within-subject crossover design. Our first hypothesis
was that oxytocin would modulate hippocampal rCBF in CHR-P
subjects. We did not hypothesise a specific effect direction
because the aim of this study was to demonstrate disease-target
(hippocampal) engagement. Secondary predictions were that its
effects would be particularly evident in the CA1 subregion, and
that it would also influence rCBF outside the hippocampus in
regions implicated in social and emotional processing.
PATIENTS & METHODS
Participants
The study received National Research Ethics Service approval (14/
LO/1692) and all subjects gave written informed consent. Thirty
male, help-seeking CHR-P individuals aged 18–35 were recruited
from two specialist early detection services—the OASIS [36] and
Tower Hamlets Early Detection Service (THEDS). A CHR-P status
was determined using the Comprehensive Assessment of At-Risk
Mental States (CAARMS) 12/2006 criteria [37]. Briefly, subjects met
one or more of the following subgroup criteria: (a) attenuated
psychotic symptoms, (b) brief limited intermittent psychotic
symptoms (BLIPS, psychotic episode lasting < 1 week, remitting
Fig. 1 Simplified schematic of proposed neural circuit mechanisms of hippocampal pathophysiology in those at CHR-P. In (1), low glutamate
signal/input from hypofunctioning NMDARs (akin to ‘faulty homeostatic sensors’) leads GABAergic interneurons to seek to homeostatically
increase excitation by reducing inhibition (disinhibition) of glutamatergic pyramidal cells. However, by disinhibiting pyramidal cells (and thus
increasing glutamate signalling) in this dysfunctional neural environment, the potential homeostatic adaptation becomes allostatic (2). In (3),
enhanced excitation leads to an overdrive in the responsivity of midbrain dopamine neurons which project to the associative striatum (note
that the connection between hippocampal pyramidal cells and midbrain dopamine neurons is presented as monosynaptic but is actually
polysynaptic via the ventral striatum and ventral pallidum). Completing the (simplified) circuit, local glutamatergic tone is increased in (4) but
is not detected as such by hypofunctioning NMDARs on GABAergic interneurons. For detailed original diagrams and discussion of evidence
for this proposed circuit or its component processes, see [7, 11, 12, 14, 74]. Glu glutame, NMDAR N-methyl-D-aspartate receptor, E/I excitation/
inhibition
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without treatment), or (c) either schizotypal personality disorder or
first-degree relative with psychosis [37], all coupled with
functional decline. Individuals were excluded if there was a
history of previous psychotic disorder (with the exception of BLIPS,
some of whom may meet acute and transient psychotic disorder
criteria [38]) or manic episode, exposure to antipsychotics,
neurological disorder or current substance-use disorder, estimated
IQ < 70, acute intoxication on the day of scanning, and any
contraindications to magnetic resonance imaging (MRI) or
intranasal oxytocin or placebo. History of Axis I disorder(s) was
not an exclusion criterion due to the transdiagnostic nature of the
CHR-P state and the high prevalence of such diagnoses within
these populations [39].Q4
Design, materials, procedure
We used a randomised, double-blind, 40 IU intranasal oxytocin vs
placebo single-dose challenge in a crossover design (1-week wash
out). During each challenge, subjects underwent an MRI scan
which started at 1130 h to minimise potential effects of diurnal
variation in oxytocin or vasopressin [27]. Anxiety was measured
using the State-Trait Anxiety Inventory (STAI) prior to each scan
(and prior to intranasal administration) so that pre-scan anxiety
score could be included in statistical models as a covariate. For
descriptive purposes, we also collected information on medication
history, use of alcohol (Alcohol Use Disorders Identification
Test, tobacco and cannabis, functioning using the Global
Functioning Role and Social scales [40] and later transition status.
Intranasal administration followed recommended guidelines and
a protocol adopted by a previous study conducted at our institute
[27]. Briefly, participants self-administered one puff (4 IU) of
intranasal oxytocin or matched placebo every 30 s, alternating
between nostrils, until 40 IU had been administered (Supplemen-
tary Materials and Methods). During the scan, participants
were asked to maintain their gaze on a centrally-placed fixation
cross.
MRI acquisition and image processing
All scans were conducted on a General Electric Discovery MR750 3
Tesla system (General Electric, Chicago, USA) using a 32-channel
head coil. Measurement of Cerebral Blood Flow (CBF) was carried
out using a 3D pseudo-continuous Arterial Spin Labeling (3D-
pCASL) sequence during two consecutive runs: 22–28 (run 1) and
30–36 (run 2) min post-intranasal administration. The timing of the
two runs was selected based on previous findings of the
spatiotemporal profile of oxytocin-induced cerebral blood flow
changes in healthy males, which demonstrated sustained effects
over a ~20–73min period (post-intranasal administration) [27]. For
each subject, we also computed a mean (average) CBF map from
the CBF maps for runs 1 and 2. ASL data were preprocessed using
the Automatic Software for ASL Processing (ASAP) 2.0 toolbox [41]
running in Statistical Parametric Mapping version 12 (SPM12;
https://www.fil.ion.ucl.ac.uk/spm/) on Matlab R2017a. 3D-pCASL
acquisition parameters and image preprocessing procedures were
conducted in line with previous studies and are detailed in the
Supplementary Materials and Methods.
Statistical analysis
Statistical analyses were performed in STATA SE14.2.
Pre-scan anxiety scores
For pre-scan anxiety (STAI) scores, missing data were imputed
using next-observation-carried-backward (Supplementary Materi-
als and Methods). Differences in pre-scan anxiety scores in the
oxytocin vs placebo conditions was assessed using a paired t-test.
In line with previous CHR-P studies [18, 19] and because anxiety
has been demonstrated to have systematic effects on CBF [42]
(including rCBF specifically in the hippocampus [43]), all analyses
included mean-centred pre-scan anxiety as a covariate.Q5
Global cerebral blood flow (CBF)
To measure global CBF signal, we used the ASAP toolbox to
extract average CBF values from a grey matter mask for each
subject. The ICBM-152 mask was obtained from the DARTEL
toolbox in SPM and thresholded to contain voxels with a >.25
probability of being grey matter. To ascertain whether global CBF
was significantly different in the oxytocin relative to placebo
conditions, we conducted repeated-measures analyses of covar-
iance (RM-ANCOVA) in STATA for run 1, run 2, and the mean of the
runs (separately), using pre-scan anxiety as covariate (Supplemen-
tary Materials and Methods). All subsequent analyses were
conducted with and without global CBF as covariate.
Hippocampal ROI rCBF
Effects of oxytocin on hippocampal rCBF were determined using a
region-of-interest (ROI) approach. A left hippocampal ROI was
defined anatomically in MNI space using the cytoarchitectonic
probabilistic atlas [44] as implemented in the Anatomy toolbox
[45] in SPM (Figs. 2a, b). The ROI mask was composed of regions
CA1, CA2, CA3, dentate gyrus, and subiculum. Mean rCBF values
for the ROI were extracted for each subject using ASAP toolbox
and entered into RM-ANCOVAs in STATA (Supplementary Materi-
als and Methods). Our primary analyses tested for effects in each
of the two runs separately. However, due to the low signal-to-
noise ratio inherent in ASL data, we also conducted an analysis of
the mean effect across the two runs, which can help to reduce
noise if the effects are stable [27]. We contained the family-wise
error (FWE) rate at α= .05 using the Hochberg procedure, which is
a 'sharper' and more powerful version of the Bonferroni
adjustment and which allows non-independence between statis-
tical tests [46]. Original p values (two-tailed) are reported
alongside indication of Hochberg correction survival (i.e., whether
or not they remain significant (survive) after accounting for FWE).
Effect sizes are reported as omega-squared (ω2).
Exploratory/supplemental analyses
We used analogous procedures to those described directly above
to extract mean rCBF values for each hippocampal subregion,
using separate masks for left CA1, CA2, CA3, dentate gyrus, and
subiculum (Fig. 3a; and Supplementary Materials and Methods).
No multiplicity correction was applied as subregion analyses were
exploratory. Finally, for completeness we examined whole-brain
effects in runs 1, 2 and the mean of the runs—separately—using
paired t-tests (second-level analysis) in SPM, with pre-scan anxiety
and with/without global CBF signal as nuisance covariates. We
conducted a whole-brain search using cluster level inference
(cluster forming threshold: p < .005; cluster reported as significant
at p < .05 using FWE correction in SPM). Analyses were restricted
using the explicit ICBM mask again thresholded to contain voxels
with >.25 probability of being grey matter.
RESULTS
Sample characteristics
Demographic and clinical characteristics of the sample are
presented in Table 1. All participants completed the study with
no drop-outs. No adverse side effects were clinically observed.
One subject was removed due to protocol violations, leaving a
sample of N= 29. There was a significant difference in pre-scan
(pre-intranasal administration) anxiety scores in the oxytocin vs
placebo condition (oxytocin [mean ± SE]= 37.4 ± 1.9; placebo=
33.4 ± 1.7; t(28)= 2.46, p= .020), which may have arisen by
chance or due to slightly more individuals receiving treatment
order oxytocin > placebo (N= 15) vs placebo > oxytocin (N= 14).
Global CBF
There was no significant difference in global grey matter CBF values
(ml/100 g/min) in the oxytocin relative to the placebo condition in
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the mean of both runs (oxytocin [marginal mean ± SE]= 52.91 ± 0.91;
placebo= 50.23 ± 0.91; F(1,27)= 4.00, p= .056) or run 1 (oxytocin=
52.89 ± 0.94; placebo= 50.44 ± 0.94; F(1,27)= 3.14, p= .088), but a
significant difference was observed in run 2 (oxytocin= 52.94 ± 0.90;
placebo= 50.03 ± 0.90; F(1,27)= 4.75, p= .038).
Hippocampal rCBF
rCBF values for all runs were log transformed due to deviations
from distributional assumptions for parametric tests. Compared to
placebo, oxytocin administration was associated with increased
hippocampal rCBF in run 1 (F(1,27)= 9.06, p= .0056; ω2= .223),
run 2 (F(1,27)= 4.96, p= .034; ω2= .124) and the mean of the 2
runs (F(1,27)= 7.31, p= .012; ω2= .184), all of which survived
Hochberg multiplicity correction (Figure S1). After controlling for
global signal effects, oxytocin administration was associated with
increased hippocampal rCBF in run 1 (F(1,26)= 7.68, p= .010; ω2
= .198) which survived multiplicity correction (Fig. 2c). The effects
were no longer evident in run 2 (F(1,26)= 0.44, p= .51; Fig. 2c) or
in the mean of the runs (F(1,26)= 3.27, p= .082). Exclusion of
participants taking antidepressants (N= 8) and benzodiazepines
(N= 1) in sensitivity analyses made no material change to the
unadjusted effects on hippocampal rCBF (Supplementary Materi-
als and Methods).
Exploratory/supplemental analyses
Hippocampal subregions. Hippocampal subregion effects were
explored in run 1 only. Relative to placebo, oxytocin administra-
tion was associated with increased rCBF in all hippocampal
subregions, including CA1 (F(1,27)= 9.44, p= .0048; ω2= .232),
CA2 (F(1,27)= 9.33, p= .0050; ω2= .229), CA3 (F(1,27)= 6.83,
p= .014; ω2= .172), subiculum (F(1,27)= 7.61, p= .010; ω2= .191)
and particularly the dentate gyrus (F(1,27)= 10.11, p= .0037;
ω2= .246)(Figure S2). After controlling for global CBF effects,
oxytocin administration was associated with increased rCBF in CA1
(F(1,26)= 7.29, p= .012; ω2= .189), CA2 (F(1,26)= 6.32, p= .018;
ω2= .165), subiculum (F(1,26)= 6.03, p= .021; ω2= .157) and
dentate gyrus (F(1,26)= 7.40, p= .011; ω2= .192), but no differ-
ence was found in CA3 (F(1,26)= 3.20, p= .086)(Fig. 3b). As noted
above, these results were not corrected for multiple comparisons.
Whole-brain. Since there was no significant difference in global
signal, unadjusted whole-brain results (including for the mean of
the runs) are reported in Table 2 (see Table S1 and Supplementary
Material for global-signal adjusted results). In run 1, oxytocin
administration was associated with increased perfusion in a large
predominantly left-lateralised cluster spanning the cerebellum,
hippocampus, parahippocampal gyrus and visual cortex, with a
peak in the cerebellum (pFWE < .05). There were no regions where
perfusion decreased after oxytocin. In run 2, oxytocin was
associated with increased perfusion in a large left-hemisphere
cluster spanning the thalamus, parahippocampal gyrus, hippo-
campus, and fusiform gyrus, with a peak in the parahippocampal
gyrus (pFWE < .05), and in a separate right-hemisphere cluster with
a peak in the superior parietal lobule (pFWE < .05).
DISCUSSION
This is the first study to investigate the neurophysiological effects
of oxytocin in CHR-P individuals. The key finding was that a single
dose of intranasal oxytocin increased resting cerebral perfusion in
the hippocampus, a region critically implicated in the pathophy-
siology of the CHR-P state and the later onset of psychosis. This
Fig. 2 rCBF Effects in Left Hippocampus. a ROI mask for the left hippocampus (yellow) overlaid on a standard brain template, and (b) overlaid
on a representative subject-level cerebral blood flow map in normalised space, and (c) bar charts showing mean hippocampal rCBF in the
oxytocin and placebo conditions in run 1 and run 2 after adjustment for global effects
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Fig. 3 rCBF in Left Hippocampal Subregions. a ROI masks for left hippocampal subregions: dentate gyrus (pink), subiculum (yellow), CA1
(cyan), CA2 (blue), and CA3 (green) displayed on a standard brain template, and (b) bar charts showing mean hippocampal subregion rCBF in
the oxytocin and placebo conditions in run 1 after adjustment for global effects
Oxytocin modulates hippocampal perfusion in people at clinical high risk. . .
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finding is consistent with the only previous study of the effects of
oxytocin on rCBF, which found left-lateralised increases in a large
limbic cluster which included the hippocampus [27]. Our analysis
of hippocampal subregions indicated that the largest effects of
oxytocin were in the dentate gyrus and CA1 (although these
analyses were exploratory and require confirmation and replica-
tion), while whole-brain analysis showed that oxytocin also
modulated perfusion in the thalamus, parietal cortex and
cerebellum.
Altered (increased) cerebral blood flow represents a core
pathophysiological mechanism for psychosis onset [7–9] and is
one of the few neuroimaging findings to have been replicated in
independent CHR-P samples [8, 18, 19]. Increased hippocampal
activity is also a key feature of preclinical models of psychosis [8,
12] and is thought to drive subcortical dopamine dysfunction [14].
Increases in hippocampal rCBF may therefore represent a disease-
modifying target [7]. In view of this literature, our analyses focused
on the hippocampal region. The left side (alone) was selected
because previous CHR-P research has repeatedly implicated the
left hippocampus in the pathophysiology of psychosis risk [7, 8,
10, 18, 20, 34, 35], with left (and not right) hippocampal blood flow
associated with clinical outcomes (i.e., remission from a CHR-P
state vs non-remission/transition to psychosis) [18]. In addition,
previous oxytocin research has reported distinctly left-lateralised
effects of oxytocin on cerebral blood flow [27].
We found that the effect of oxytocin on hippocampal rCBF in
run 2 became non-significant after controlling for global signal.
This may have reflected poorer signal-to-noise ratio in run 2 than
run 1, as inspection of the raw data suggested there was greater
variance in both hippocampal rCBF and global CBF values.
Another possibility is that it was related to the much more
pronounced effects of oxytocin on global rCBF during run 2 than
in run 1. A final consideration is that our findings were influenced
by the time course and dose-response effects of oxytocin, which
may follow an inverted U-shaped curve [47, 48].
In exploratory analyses, we found that oxytocin increased rCBF
in all of the hippocampal subregions that were examined, with the
largest effects in the dentate gyrus and in CA1 (other subregions
are discussed in the Supplementary Material). Previous neuroima-
ging research in CHR-P individuals suggests that CA1 is a key locus
of dysfunction [8, 15]. The CA1 region plays an integral role in
social and autobiographical memory [49], and CHR-P individuals
show impairments in these domains [50]. In healthy individuals,
oxytocin enhances social learning [51] and memory [24]. CA1
dysfunction is also at the centre of pathophysiological processes
implicated in the onset of psychosis [7]; transition and/or non-
remission from a CHR-P state is associated with enhanced CA1
perfusion and hypermetabolism [8, 18] and a gradual decline in
CA1 volume [15]. Compared to other hippocampal subregions,
CA1 has the highest number of GABAergic interneurons [15, 52]
and an N-methyl-D-aspartate receptor (NMDAR) expression profile
which confers enhanced susceptibility to glutamatergic alterations
and excitotoxicity [53] – key features of the proposed neural
circuit underlying psychosis onset [7]. In preclinical studies,
oxytocin modulates this neural circuit by targeting GABAergic
interneuron function and enhancing the signal-to-noise ratio of
CA1 pyramidal cell firing [28, 29].
In terms of the dentate gyrus, CHR-P individuals whose
symptoms had remitted were recently shown to have a long-
itudinal reduction in left hippocampal perfusion [18], which
reference to a cytoarchitectonic atlas [44, 45] indicates had its
peak coordinate in the left dentate gyrus. Another study reported
reduced dentate gyrus volumes in CHR-P patients vs controls [17].
The dentate gyrus is thought to function as a computational
pattern separator, with dysfunction here mechanistically linked to
NMDAR hypofunction [54] and generation of spurious associations
that may contribute to the onset of psychotic symptoms [55].
Patients with first-episode psychosis show deficits in pattern
separation, which can be recreated in healthy volunteers using
ketamine (NMDAR antagonist) challenge [54]. Interestingly,
oxytocin is thought to exert its facilitatory effects on social
recognition and behaviour via oxytocin receptors in the dentate
gyrus, which recruit pattern separation circuits to minimise
interference between similar social memories -at least in
preclinical models [56]. In rats, activation of oxytocin receptors
drives GABA release in the dentate gyrus in an action potential-
dependent manner [57], and exogenous oxytocin has stimulatory
effects on cell proliferation and adult neurogenesis, even under
conditions of stress and elevated glucocorticoids, which also
appears to be specific to the dentate gyrus [58]. These findings
further demonstrate that oxytocin engages key pathophysiologi-
cal circuits that are associated with the onset of psychosis.
We also investigated the effects of oxytocin at the whole-brain
level. We found that oxytocin was associated with increased
perfusion in large clusters spanning the hippocampus, para-
hippocampal gyrus and fusiform gyrus, as well as the cerebellum,
and in run 2, the thalamus. Effects in these regions are consistent
with previous work on (a) the effects of oxytocin on perfusion in
healthy individuals [27], (b) high levels of oxytocin pathway gene
Table 1. Participant demographic and clinical characteristics
Variable Total sample
(N= 30)
Demographic Age, years; mean (SD) 23.2 (4.7)
Age range, years 18–35
Sex, male/female 30/0
Ethnicity (White/Black/Asian/Mixed) 16/6/4/4
Handedness, right/left 26/4
Education, years; mean (SD) 13.2 (1.9)
Clinical CHR-P Subtypea (BLIPS/APS/GRD) 6/23/1
CAARMS attenuated positive
symptomsb; mean (SD)
11.7 (3.3)
Transition to psychosis (yes/no)c 4/26
Baseline anxiety scored; mean (SD) 35.6 (8.7)
GF social score; mean (SD) 6.8 (1.5)
GF role score; mean (SD) 7.0 (1.7)
Current antidepressant medication
(yes/no)
8/22
Current antipsychotic medication
(yes/no)
0/30
Current benzodiazepine medication
(yes/no)
1/29
Substance Use Current smoker (yes/no) 17/13
Cigarettes/day; mean (SD) 9.8 (6.0)
Cannabis usee; median (range) 2 (0–4)
Alcohol, AUDIT total; mean (SD) 7.2 (7.7)
aComprehensive Assessment of At-Risk Mental States (CAARMS) subgroup;
BLIPS brief limited intermittent psychotic symptoms, APS attenuated
psychotic symptoms, GRD genetic risk and deterioration
bSum of the global (severity) ratings for positive subscale items (P1-P4) of
the CAARMS
cThe 4 transitions occurred within 26 months but the follow up is still
ongoing
dMean of pre-scan anxiety scores across conditions as measured by the
State Trait Anxiety Inventory (STAI)
eCannabis use: 0= never, 1= experimental use (tried occasionally), 2=
occasional use (small quantities from time to time), 3=moderate use
(moderate quantities regularly / large amounts occasionally), 4= severe
use (frequently used large quantities, often to intoxication/debilitation).
AUDIT alcohol use disorders identification test, CHR-P clinical high risk for
psychosis, GF global functioning (role and social) scale
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expression and mRNA in the hippocampus, parahippocampal
gyrus and thalamus (preprint [59]), and (c) the role of these
regions in emotion processing and social cognition [21, 60, 61].
Increased perfusion was observed -albeit as part of a large cluster-
in the left posterior hippocampus (including CA1 and dentate
gyrus) at the whole-brain level across all runs, despite not
surviving adjustment for global signal effects. The left-lateralised
temporal lobe findings are in line with previous oxytocin work [27,
47, 60, 62] and predominantly left-hemisphere ROIs used in CHR-P
neuroimaging studies [34, 63].
A separate healthy control group was not included in the
current study because two previous independent CHR-P samples
recruited from the same clinical service - the OASIS - have shown
that hippocampal perfusion is altered in CHR-P individuals vs
controls. These studies were large and the findings replicated,
thus providing a priori evidence of hippocampal rCBF alterations
in CHR-P individuals. Thus, we have used ROIs based on previous
studies that reflect validated CHR-P vs control differences.
However, future studies that include a parallel group of healthy
volunteers would allow examination of the specificity and
potential differential effects of oxytocin in CHR-P vs normative
samples, as well as aiding the interpretation of the direction
(increase vs decrease) of cerebral blood flow effects. Because we
only tested one relatively mid-to-high range dose of oxytocin
(40IU, which may be sufficient to cross-react with vasopressin
receptors to give a vasopressin-like effect [64, 65]), we were not
able to evaluate whether lower doses would show different effects
(i.e., reduction of hippocampal perfusion). Given that previous
studies have reported increased hippocampal perfusion in people
at CHR-P [8, 18, 19], it may well be that a reduction in perfusion is
the ultimate therapeutic target. These investigations were not
possible in the current study, which was primarily an acute
challenge to demonstrate disease-target engagement, but they
provide the first evidence that intranasal oxytocin can alter
cerebral blood flow in CHR-P individuals in target brain regions.
Furthermore, while initial evidence of direct nose-to-brain
transport has recently emerged [66], the exact mechanism by
which it enters the brain is not fully understood, and differences in
nasal anatomy and administration technique could influence the
amount of oxytocin that reaches the brain. Our crossover (and
counterbalanced order) design helped to control for this, but
future research could use novel devices which may provide a
more consistent and optimised delivery of oxytocin. Although
none of the CHR-P participants were taking antipsychotic
medication, a minority were taking antidepressants (N= 8) or
benzodiazepines (N= 1), which could have affected the results.
However, excluding these subjects did not alter the main results.
We also excluded female subjects due to sexual dimorphism in
oxytocinergic function [48, 60]. We did not include specific
behavioural or symptom data because the study was designed
(and therefore powered) to investigate the neurophysiological
basis for the effects of oxytocin and to primarily show disease-
target engagement. Finally, findings in CHR-P subjects can be
influenced by sampling biases that modulate the level of risk for
Table 2. Effects of oxytocin vs placebo on whole-brain CBF (without adjustment for global CBF effects)
Cluster Description Hemis-
phere
k P(FWE-corr) Peak
coordinates
Peak description
x y z
Run 1, Oxytocin > Placebo
Left cerebellum, visual cortex, parahippocampal gyrus, hippocampus,
fusiform gyrus, lingual gyrus; right cuneus, calcarine gyrus, visual cortex,
cerebellum
Left 3904 <.05 −26 −32 −36 Cerebellum (culmen)
−20 −46 −28 Cerebellum (culmen)
−24 −72 −2 Lingual gyrus
Run 1, Placebo > Oxytocin
None
Run 2, Oxytocin > Placebo
Left cerebellum, fusiform gyrus, parahippocampal gyrus, hippocampus,
lingual gyrus, thalamus; right cerebellum
Left 3117 <.05 −36 −44 −8 Parahippocampal gyrus
−2 −80 −34 Cerebellum (pyramis)
−16 −58 −12 Cerebellum (culmen)
Right superior parietal lobule, precuneus, calcarine gyrus, cuneus, visual
cortex; left visual cortex
Right 2394 <.05 22 −60 68 Superior parietal lobule
8 −48 74 Postcentral gyrus
4 −82 28 Cuneus
Run 2, Placebo > Oxytocin
None
Mean of the runs, Oxytocin > Placebo
Left cerebellum, parahippocampal gyrus, hippocampus, fusiform gyrus,
thalamus, lingual gyrus, visual cortex; right cuneus, visual cortex,
cerebellum
Left 5348 <.05 −26 −32 −36 Cerebellum (culmen)
−26 −48 20 White matter
−30 −48 10 White matter
Mean of the runs, Placebo > Oxytocin
None
k number of voxels in the cluster, pFWE FWE-corrected p-value
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psychosis [67], but the level of risk in subjects from our local CHR-P
clinic [36] has remained stable over recent years [68].
CHR-P individuals show deficits in social cognition [69] and
altered neural responses during social and emotion processing
fMRI tasks [70], which may contribute to a reduction in social and
occupational functioning. Because oxytocin can have prosocial
effects in healthy volunteers [23, 25] and in patients with
schizophrenia [71], and modulates brain activation during social
and emotion processing fMRI paradigms [72], this suggests that it
might -subject to future research- be useful as a novel treatment
in CHR-P subjects. However, while our results are promising in
showing that oxytocin can engage brain regions strongly
implicated in the onset of psychosis, they do not tell us about
effects on symptoms, functioning, social cognition or any other
CHR-P presentation, which limits the clinical interpretability of our
findings. These outcomes remain important avenues for future
research and we envisage that this study will provide the
neurophysiological evidence in support of future longer-term
clinical trials that can provide clinical validation. Furthermore,
oxytocin has a good side effect profile; it is safe and well tolerated
[73], and none of our participants reported adverse effects. At
present, there are no licensed pharmacological treatments for this
group, and although psychological interventions have been
recommended, there is limited evidence that these are effective
[2, 3]. Developing effective treatments for CHR-P subjects thus
represents an unmet clinical need.
CONCLUSIONS
The present study indicates that a single dose of oxytocin can
significantly modulate hippocampal perfusion in people at CHR for
psychosis. This suggests that oxytocin merits further investigation
as a candidate novel treatment for this group.
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